Wen Xiajie, Lu Fengmin, Liu Shuang
Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou.
Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou; Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center.
Onco Targets Ther. 2016 Dec 8;9:7425-7433. doi: 10.2147/OTT.S121594. eCollection 2016.
Several previous studies have investigated the association between gene () mutation and the poor outcome of primary liver cancer (PLC) patients; however, the results remain inconsistent. In the present study, mutation in 60 paired tumor and corresponding nontumor tissues derived from a cohort of 60 PLC patients was systematically analyzed. The results showed that mutation was only an independent risk factor for overall survival (OS), not for recurrence-free survival (RFS), and a meta-analysis was performed to verify this. Online databases were searched up to July 1, 2016. Studies about the association between mutation and the postsurgery survival of PLC patients were collected. A total of 988 patients from eight studies were analyzed; among them, 341 (34.51%) patients had mutation. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were 2.03 (1.64, 2.41) and 2.36 (1.31, 3.42) for OS and RFS, respectively. In conclusion, both the cohort study and meta-analysis suggested that the mutation was associated with postsurgery OS in Asian PLC patients. However, the relationship between mutation and recurrence should be confirmed by further studies.
此前已有多项研究探讨了基因（）突变与原发性肝癌（PLC）患者不良预后之间的关联；然而，结果仍不一致。在本研究中，对来自60例PLC患者队列的60对肿瘤及相应非肿瘤组织中的突变进行了系统分析。结果显示，突变仅是总生存期（OS）的独立危险因素，而非无复发生存期（RFS）的独立危险因素，并进行了荟萃分析以验证这一点。检索在线数据库至2016年7月1日。收集了关于突变与PLC患者术后生存之间关联的研究。共分析了八项研究中的988例患者；其中，341例（34.51%）患者存在突变。OS和RFS的合并风险比（HR）及95%置信区间（CI）分别为2.03（1.64，2.41）和2.36（1.31，3.42）。总之，队列研究和荟萃分析均表明，突变与亚洲PLC患者术后OS相关。然而，突变与复发之间的关系仍需进一步研究证实。
